Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 138Lymphoma, Non-Hodgkin 84Lymphoma, Large B-Cell, Diffuse 83Small Cell Lung Carcinoma 78Hodgkin Disease 61Precursor Cell Lymphoblastic Leukemia-Lymphoma 59Leukemia 57Burkitt Lymphoma 56Lung Neoplasms 49Lymphoma, Follicular 47Lymphoma, Mantle-Cell 44Leukemia, Myeloid, Acute 41Lymphoma, Large-Cell, Immunoblastic 40Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 33Carcinoma, Non-Small-Cell Lung 30Recurrence 26Neuroblastoma 25Lymphoma, B-Cell, Marginal Zone 25Central Nervous System Neoplasms 24Ovarian Neoplasms 18Sarcoma 17Brain Neoplasms 17Dendritic Cell Sarcoma, Interdigitating 16Congenital Abnormalities 16Lymphoma, Large-Cell, Anaplastic 15Breast Neoplasms 15Testicular Neoplasms 14Neoplasms, Plasma Cell 14Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 13

Interventions

Cyclophosphamide 5Rituximab 3fludarabine phosphate 2fludarabine 2dacetuzumab 2cobomarsen 2blinatumomab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Ifosfamide 2Etoposide 2Doxorubicin 2Carboplatin 2Busulfan 2pembrolizumab 1Vorinostat 1CLR1404 1Brentuximab Vedotin 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Immunoproliferative Disorders × Etoposide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡